TABLE 2.

Ocular Adverse Events Reported in ≥5% of Patients in Either Treatment Arm

	Once-daily Netarsudil 0.02% (n=839)	Twice-daily Timolol 0.5% (n=839)
Eye disorders
Conjunctival hyperemia	456 (54.4)	87 (10.4)
Cornea verticillata	175 (20.9)	2 (0.2)
Conjunctival hemorrhage	144 (17.2)	15 (1.8)
Vision blurred	62 (7.4)	12 (1.4)
Lacrimation increased	60 (7.2)	5 (0.6)
Erythema of eyelid	57 (6.8)	6 (0.7)
Visual acuity reduced	44 (5.2)	13 (1.5)
Administration site conditions
Instillation site pain	167 (19.9)	181 (21.6)
Instillation site erythema	76 (9.1)	13 (1.5)
Investigations
Vital dye staining cornea present	79 (9.4)	64 (7.6)

Data are expressed as number (%) of patients.